ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer

详细信息    查看全文

• 作者：Christian Marth^a ; ^{Christian.MARTH@tirol-kliniken.at} ; Ignace Vergote^b ; Giovanni Scambia^c ; Willi Oberaigner^d ; Andrew Clamp^e ; Regina Berger^a ; Christian Kurzeder^f ; Nicoletta Colombo^g ; Peter Vuylsteke^h ; Domenica Lorussoⁱ ; Marcia Hall^j ; Vincent Renard^k ; Sandro Pignata^l ; Rebecca Kristeleit^m ; Sevilay Altintasⁿ ; Gordon Rustin^j ; Robert M. Wenham^o ; Mansoor Raza Mirza^p ; Peter C. Fong^q ; Amit Oza^r ; Bradley J. Monk^s ; Haijun Ma^t ; Florian D. Vogl^t ; Bruce A. Bach^t
• 关键词：ENGOT-ov-6/TRINOVA-2 ; Trebananib ; Pegylated liposomal doxorubicin ; Progression-free survival ; Objective response rate ; Duration of response
• 刊名：European Journal of Cancer
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：70
• 期：Complete
• 页码：111-121
• 全文大小：984 K
• 卷排序：70

文摘

Trebananib + PLD did not meet the primary end-point of improving PFS. However, trebananib + PLD improved objective response rate and duration of response. No new safety signals were identified in the ENGOT-ov-6/TRINOVA-2 study.